Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

GSM6454742

· D

4a294b45-2eea-5e7d-b929-7c213fdfa08d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.310
  • WNT_BETA_CATENIN_SIGNALING+0.280
  • P53_PATHWAY+0.200
  • HEDGEHOG_SIGNALING+0.170
  • MYOGENESIS+0.170
  • ALLOGRAFT_REJECTION+0.150
  • APICAL_JUNCTION+0.110
  • APICAL_SURFACE+0.100
  • IL6_JAK_STAT3_SIGNALING+0.090
  • TGF_BETA_SIGNALING+0.070

Top 10 suppressed

  • PROTEIN_SECRETION-0.590
  • MYC_TARGETS_V1-0.490
  • OXIDATIVE_PHOSPHORYLATION-0.410
  • MTORC1_SIGNALING-0.390
  • ANDROGEN_RESPONSE-0.370
  • E2F_TARGETS-0.350
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
  • UNFOLDED_PROTEIN_RESPONSE-0.350
  • ADIPOGENESIS-0.340
  • ANGIOGENESIS-0.320

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR12696780
melanoma-umap@29
0.857
2MNG1087
mng-umap@100
0.855
3R186
bladder-landscape@3
0.852
49176b038-65e3-469d-a867-d99bc732e45d
colon-landscapes@1
0.846
5MNG1258
mng-umap@100
0.840
6d406bb03-1a9a-4aa3-a1a8-4de5478b4701
colon-landscapes@1
0.836
7SRR4195667
colon-landscapes@1
0.831
8SRR8942953
bladder-landscape@3
0.827
9MBCProject_0003_T2_RNA
breast-umap@18
A0.817
10R96
bladder-landscape@3
0.816

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 11 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.310Remibrutinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.280Inavolisib— uncovered
P53_PATHWAY0.200Idelalisib— uncovered
HEDGEHOG_SIGNALING0.170Inavolisib— uncovered
MYOGENESIS0.170Inavolisib— uncovered
ALLOGRAFT_REJECTION0.150Idelalisib— uncovered
APICAL_JUNCTION0.110Inavolisib— uncovered
APICAL_SURFACE0.100Temsirolimus— uncovered
IL6_JAK_STAT3_SIGNALING0.090Inavolisib— uncovered
TGF_BETA_SIGNALING0.070Inavolisib— uncovered
NOTCH_SIGNALING0.010Inavolisib— uncovered